Mohammadi Mahya, Aghanajafi Cyrus, Soltani M, Raahemifar Kaamran
Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran 19967-15433, Iran.
Department of Applied Mathematics, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Pharmaceutics. 2022 Feb 5;14(2):363. doi: 10.3390/pharmaceutics14020363.
This study numerically analyzes the fluid flow and solute transport in a solid tumor to comprehensively examine the consequence of normalization induced by anti-angiogenic therapy on drug delivery. The current study leads to a more accurate model in comparison to previous research, as it incorporates a non-homogeneous real-human solid tumor including necrotic, semi-necrotic, and well-vascularized regions. Additionally, the model considers the effects of concurrently chemotherapeutic agents (three macromolecules of IgG, F(ab')2, and F(ab')) and different normalization intensities in various tumor sizes. Examining the long-term influence of normalization on the quality of drug uptake by necrotic area is another contribution of the present study. Results show that normalization decreases the interstitial fluid pressure (IFP) and spreads the pressure gradient and non-zero interstitial fluid velocity (IFV) into inner areas. Subsequently, wash-out of the drug from the tumor periphery is decreased. It is also demonstrated that normalization can improve the distribution of solute concentration in the interstitium. The efficiency of normalization is introduced as a function of the time course of perfusion, which depends on the tumor size, drug type, as well as normalization intensity, and consequently on the dominant mechanism of drug delivery. It is suggested to accompany anti-angiogenic therapy by F(ab') in large tumor size (Req=2.79 cm) to improve reservoir behavior benefit from normalization. However, IgG is proposed as the better option in the small tumor (Req=0.46 cm), in which normalization finds the opportunity of enhancing uniformity of IgG average exposure by 22%. This study could provide a perspective for preclinical and clinical trials on how to take advantage of normalization, as an adjuvant treatment, in improving drug delivery into a non-homogeneous solid tumor.
本研究对实体瘤中的流体流动和溶质传输进行了数值分析,以全面考察抗血管生成疗法诱导的正常化对药物递送的影响。与先前的研究相比,当前的研究得出了一个更准确的模型,因为它纳入了一个非均匀的真实人类实体瘤,包括坏死、半坏死和血管丰富的区域。此外,该模型考虑了同时使用化疗药物(IgG、F(ab')2和F(ab')三种大分子)以及不同肿瘤大小下不同正常化强度的影响。考察正常化对坏死区域药物摄取质量的长期影响是本研究的另一项贡献。结果表明,正常化降低了间质液压力(IFP),并将压力梯度和非零间质液速度(IFV)扩展到内部区域。随后,药物从肿瘤周边的清除减少。还表明,正常化可以改善间质中溶质浓度的分布。正常化效率被定义为灌注时间过程的函数,这取决于肿瘤大小、药物类型以及正常化强度,进而取决于药物递送的主导机制。建议在大肿瘤尺寸(Req = 2.79 cm)中联合使用F(ab')进行抗血管生成治疗,以从正常化中受益并改善储库行为。然而,对于小肿瘤(Req = 0.46 cm),IgG被认为是更好的选择,在这种情况下,正常化有机会将IgG平均暴露的均匀性提高22%。本研究可为临床前和临床试验提供一个视角,即如何利用正常化作为辅助治疗手段,来改善药物向非均匀实体瘤的递送。